Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproate population pharmacokinetics in children.

B B Serrano1, M J García Sánchez, M J Otero

  • 1Pharmacy Service, University Hospital, Salamanca, Spain.

Journal of Clinical Pharmacy and Therapeutics
|May 13, 1999
PubMed
Summary

This study developed a population pharmacokinetic model for valproic acid (VPA) in children with epilepsy. The model accurately predicts VPA clearance based on total body weight, daily dose, and carbamazepine (CBZ) comedication, improving dosage regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Observation of B(s)(0) → J/ψf(2)'(1525) in J/ψK+ K- final states.

Physical review letters·2012
Same author

Evidence for CP violation in time-integrated D0→h(-)h(+) decay rates.

Physical review letters·2012
Same author

Search for lepton number violating decays B+ → π- μ+ μ+ and B+ → K- μ+ μ+.

Physical review letters·2012
Same author

Measurement of the CP-violating phase ϕ(s) in the decay B(s)(0) → J/ψϕ.

Physical review letters·2012
Same author

Serum proteomic profiling in patients with drug-induced liver injury.

Alimentary pharmacology & therapeutics·2012
Same author

Determination of f(s)/f(d) for 7 TeV pp collisions and measurement of the B0→D-K+ branching fraction.

Physical review letters·2011

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Pediatric Epilepsy Treatment
  • Drug Metabolism and Interactions

Background:

  • Valproic acid (VPA) is a widely used antiepileptic drug in children.
  • Accurate VPA dosing is crucial for efficacy and safety, but inter-individual variability in clearance is significant.
  • Existing pharmacokinetic models may not fully capture factors influencing VPA clearance in pediatric populations.

Purpose of the Study:

  • To develop a population pharmacokinetic model for valproic acid (VPA) in pediatric epilepsy patients.
  • To identify key covariates influencing VPA clearance (CL).
  • To improve the prediction of VPA serum concentrations for optimized dosing strategies.

Main Methods:

  • Population pharmacokinetic analysis of 770 VPA serum concentration samples from 255 children (0.1-14 years).

Related Experiment Videos

  • Utilized the NONMEM program with a one-compartment model, fixing absorption and distribution parameters.
  • Covariates evaluated included age, total body weight (TBW), VPA dose, sex, and carbamazepine (CBZ) comedication.

    • Main Results:

    • A final model identified TBW, VPA daily dose, and CBZ comedication as significant predictors of VPA clearance.
    • The model demonstrated improved predictive performance compared to a covariate-free model (RMSE 19.50 vs. 39.73 mg/l).
    • Interpatient variability in CL was 21.4% and residual variability was 23.9%.

    Conclusions:

    • A population pharmacokinetic model for VPA in pediatric patients has been established.
    • The model effectively estimates individual VPA clearance based on dose, weight, and CBZ use.
    • This model facilitates a priori dosage regimen optimization for children with epilepsy.